DanielGBruetmanMDMMM

Medical Oncologist

Overview of Dr. Bruetman

Dr. Daniel Bruetman is an oncologist in Chicago, IL and is affiliated with City of Hope Chicago. He received his medical degree from University of Buenos Aires and has been in practice 34 years. Dr. Bruetman accepts several types of health insurance, listed below. He is one of 24 doctors at City of Hope Chicago who specialize in Oncology. He also speaks multiple languages, including Spanish.

Office
160 E. Illinois Street
Chicago, IL 60611
Book by Phone+1(847) 534-5618
Is this information wrong?

Education & Training

Carnegie Mellon UniversityMaster in Medical Management(MMM), 2007 - 2008
Rush University Medical CenterFellowship, Hematology and Medical Oncology, 1987 - 1989
Advocate Health Care/Advocate Christ Medical CenterResidency, Internal Medicine, 1984 - 1987
University of Buenos AiresClass of 1983

Certifications & Licensure

IL State Medical License 1984 - 2026
IN State Medical License 2001 - 2021
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Clinical Trials

Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer Start of enrollment: 2012 Apr 01
Terminated
Phase 2
Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer Start of enrollment: 2013 Feb 01
Completed
Phase 2
Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer Start of enrollment: 2013 Oct 22
Active, not recruiting
Phase 1, Phase 2
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer Start of enrollment: 2015 Jul 26
Recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

Updated survival and outcomes for older adults with inoperable stage III non-small-cell lung cancer treated with cisplatin, etoposide, and concurrent chest radiation w...
Jalal, S. I., Riggs, H. D., Melnyk, A., Richards, D., Agarwala, A., Neubauer, M., Ansari, R., Govindan, R., Bruetman, D., Fisher, W., Breen, T., Johnson, C. S., Yu, M....> ;Ann Oncol. 2012 Jul
Phase III trial of cisplatin (P) plus etoposide (E) plus concurrent chest radiation (XRT) with or without consolidation docetaxel (D) in patients (pts) with inoperable...
Mina LA, Neubauer MA, Ansari RH, Govindan R, Einhorn LH, Fisher W, Bruetman D, Chowhan NM, Johnson C, Hanna NH> ;J. Clin. Oncol.. 2008-05-20
Phase III study of cisplatin (P) plus etoposide (E) with concurrent chest radiation (XRT) followed by docetaxel (D) vs. observation in patients (pts) with stage III no...
Bedano PM, Neubauer M, Ansari R, Govindan R, Einhorn LH, Bruetman D, White A, Breen T, Juliar B, Hanna N> ;J. Clin. Oncol.. 2006-06-20
Pemetrexed in patients (pts) with relapsed small cell lung cancer (SCLC): A phase II study from the Hoosier Oncology Group.
Hanna NH, Ansari R, Bhatia S, Govindan R, Bruetman D, Hosford M, Fisher W, White A, Breen T, Juliar B> ;J. Clin. Oncol.. 2006-06-20
Gefitinib plus celecoxib in chemotherapy-naïve patients with stage IIIB/IV non-small cell lung cancer (NSCLC): A phase II study from the Hoosier Oncology Group.
Agarwala AK, Einhorn L, Fisher W, Bruetman D, McClean J, Taber D, Titzer M, Juliar B, Breen T, Hanna N> ;J. Clin. Oncol.. 2006-06-20
Differentiating agents in malignant disease.
Daniel G. Bruetman, Jules E. Harris, Kenning M. Anderson> ;Medical and Pediatric Oncology. 1991 Jan 1
Ductal carcinoma in situ of the breast.
Bruetman D, Bloom K, Bines S> ;Medical and Pediatric Oncology. 1989 Jan 1
Pemetrexed in second line and beyond small cell lung cancer: a Hoosier Oncology Group phase II study.
Jalal, S., Ansari, R., Govindan, R., Bhatia, S., Bruetman, D., Fisher, W., Masters, G., White, A., Stover, D., Yu, M., Hanna, N.> ;J Thorac Oncol. 2009 Jan 01
Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lu...
Hanna, N., Neubauer, M., Yiannoutsos, C., McGarry, R., Arseneau, J., Ansari, R., Reynolds, C., Govindan, R., Melnyk, A., Fisher, W., Richards, D., Bruetman, D., Anders...> ;J Clin Oncol. 2008 Dec 10
Gefitinib plus celecoxib in chemotherapy-naïve patients with stage IIIB/IV non-small cell lung cancer: a phase II study from the Hoosier Oncology Group.
Agarwala, A., Fisher, W., Bruetman, D., McClean, J., Taber, D., Titzer, M., Juliar, B., Yu, M., Breen, T., Einhorn, L. H., Hanna, N.> ;J Thorac Oncol. 2008 Apr
Join now to see all

Press Mentions

Efficacy of Margetuximab vs Trastuzumab in Patients with Pretreated ERBB2-Positive Advanced Breast CancerJanuary 22nd, 2021
74 Oncologists on the MoveOctober 11th, 2023

Professional Memberships

American Society of Clinical Oncology - ASCO
Member

Other Languages

Spanish

Hospital Affiliations

City of Hope ChicagoZion, Illinois

Insurance Accepted

Aetna Choice POS II
Anthem Blue Access PPO
Anthem Blue Preferred HMO
BCBS Blue Card PPO
BCBS Illinois PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Cofinity PPO
First Health PPO
Great West PPO
Humana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PPO
Sagamore Health Plus
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment